Archives of Pediatric Infectious Diseases

Published by: Kowsar

Susceptibility Pattern of Bacille Calmette-Guerin Strains Against Pyrazinamide and Other Major Anti-Mycobacterial Drugs

Seyed Alireza Fahimzad 1 , Mahmood Ghasemi 2 , Farideh Shiva 1 , Keyghobad Ghadiri 2 , Masoumeh Navidinia 3 and Abdollah Karimi 1 , *
Authors Information
1 Pediatric Infections Research Center, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Nosocomial Infection Research Center, Kermanshah University of Medical Sciences, Kermanshah, IR Iran
3 Department of Laboratory Sciences, Paramedical Sciences Faculty, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Pediatric Infectious Diseases: January 01, 2015, 3 (1 TB); e17814
  • Published Online: January 26, 2015
  • Article Type: Research Article
  • Received: January 24, 2014
  • Revised: March 12, 2014
  • Accepted: June 28, 2014
  • DOI: 10.5812/pedinfect.17814

To Cite: Fahimzad S A, Ghasemi M, Shiva F, Ghadiri K, Navidinia M, et al. Susceptibility Pattern of Bacille Calmette-Guerin Strains Against Pyrazinamide and Other Major Anti-Mycobacterial Drugs, Arch Pediatr Infect Dis. 2015 ; 3(1 TB):e17814. doi: 10.5812/pedinfect.17814.

Abstract
Copyright © 2015, Pediartric Infections Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Netto EM, Dye C, Raviglione MC. Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Global Monitoring and Surveillance Project. Int J Tuberc Lung Dis. 1999; 3(4): 310-20[PubMed]
  • 2. Reported tuberculosis in the United States, 2006. 2007;
  • 3. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006; 194(4): 479-85[DOI][PubMed]
  • 4. Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev. 2008; 32(5): 821-41[DOI][PubMed]
  • 5. The Pasteur Institute of Iran seen by Marcel Baltazard. 2004;
  • 6. Lotte A, Wasz-Hockert O, Poisson N, Dumitrescu N, Verron M, Couvet E. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res. 1984; 21: 107-93[PubMed]
  • 7. Caviedes L, Lee TS, Gilman RH, Sheen P, Spellman E, Lee EH, et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru. J Clin Microbiol. 2000; 38(3): 1203-8[PubMed]
  • 8. Jeffrey RS. Textbook of Pediatric Infectious Diseases. 2009; : 1426-69
  • 9. Nazir Z, Qazi SH. Bacillus Calmette-Guerin (BCG) lymphadenitis-changing trends and management. J Ayub Med Coll Abbottabad. 2005; 17(4): 16-8[PubMed]
  • 10. Turnbull FM, McIntyre PB, Achat HM, Wang H, Stapledon R, Gold M, et al. National study of adverse reactions after vaccination with bacille Calmette-Guerin. Clin Infect Dis. 2002; 34(4): 447-53[DOI][PubMed]
  • 11. Deeks SL, Clark M, Scheifele DW, Law BJ, Dawar M, Ahmadipour N, et al. Serious adverse events associated with bacille Calmette-Guerin vaccine in Canada. Pediatr Infect Dis J. 2005; 24(6): 538-41[PubMed]
  • 12. Fine P, E. M, Carneiro IAM, Milstien J, B, Clements CJ. Issues relating to the use of BCG in immunization programmes. World Health Organization. 1999; 45
  • 13. de Jong BC, Onipede A, Pym AS, Gagneux S, Aga RS, DeRiemer K, et al. Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis? J Clin Microbiol. 2005; 43(7): 3530-2[DOI][PubMed]
  • 14. Cunha J. Pyrazinamide susceptibility testing in all isolates of the Mycobacterium tuberculosis complex - a critical analysis. Rev Port Pneumol. 2012; 18(4): 188-9[DOI][PubMed]
  • 15. Piersimoni C, Mustazzolu A, Giannoni F, Bornigia S, Gherardi G, Fattorini L. Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum. J Clin Microbiol. 2013; 51(1): 291-4[DOI][PubMed]
  • 16. Human tuberculosis caused by Mycobacterium bovis--New York City, 2001-2004. MMWR Morb Mortal Wkly Rep. 2005; 54(24): 605-8[PubMed]
  • 17. Shishido Y, Mitarai S, Otomo K, Seki M, Sato A, Yano I, et al. Anti-tuberculosis drug susceptibility testing of Mycobacterium bovis BCG Tokyo strain. Int J Tuberc Lung Dis. 2007; 11(12): 1334-8[PubMed]
  • 18. Durek C, Rusch-Gerdes S, Jocham D, Bohle A. Sensitivity of BCG to modern antibiotics. Eur Urol. 2000; 37 Suppl 1: 21-5[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments